TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30305092
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (otic gel and suspension)
Study: 8345370
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with 30 micrograms/kg intravenous (i.v.) alfentanil, 2.5 mg/kg i.v. thiopental, and 0.1 mg/kg i.v. vecuronium, maintained with 0.5 microgram/kg/min alfentanil, nitrous oxide (N2O) 67% in oxygen, and 0.8 microgram/kg/min vecuronium.
Study: 8345370
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy with one of three different treatment modalities (20 to 60 micrograms/kg i.v. alfentanil, 0.5 to 2.0% inspired isoflurane, or 0.05 to 0.15 mg/kg i.v. trimethaphan).
Study: 3946979
Drug: Dialysate Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate Ca concentration of 7.5 mg/dL
Study: 3946979
Drug: Dialysate Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate Ca concentration of 5.5 mg/dL
Study: 25330687
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg-norgestimate 250 mcg-ethinyl estradiol 35 microg (Group A)
Study: 25330687
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 12 mg-ethinyl estradiol 35 microg (Group B)
Study: 25330687
Drug: Norgestimate 250
Normalized name: ethinyl estradiol 25 MCG / norgestimate 250 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate 250 mcg-ethinyl estradiol 35 microg (Group C)
Study: 23031562
Drug: LND +
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LND + RE (low energy, low CP diet with 50 mg/kg NSP-hydrolysing enzyme)
Study: 23031562
Drug: HND +
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HND + RE (high energy, high CP diet with 50 mg/kg NSP-hydrolysing enzyme)
Study: 18338628
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) theory
Study: 6388916
Drug: Budesonide (freon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (freon propellant device - Rhinocort) 400 micrograms daily
Study: 6388916
Drug: Budesonide (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (water solution in mechanical pump spray) 400 micrograms daily
Study: 6388916
Drug: Budesonide (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (water solution in mechanical pump spray) 200 micrograms daily
Study: 28961958
Drug: Online life
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online life review therapy with online counseling
Study: 28961958
Drug: Online life
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online life review therapy with online peer support
Study: 17537772
Drug: Beta-lactam macrolide
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam macrolide combination therapy
Study: 17537772
Drug: Beta-lactam alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam alone monotherapy
Study: 17537772
Drug: Matched groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched groups (27 patients each from monotherapy and combination therapy)
Study: 10068095
Drug: Interferon monotherapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon monotherapy (6 months)
Study: 10068095
Drug: Interferon monotherapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon monotherapy (up to 12 months)
Study: 10068095
Drug: Interferon-ribavirin combination
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon-ribavirin combination therapy (6 months)
Study: 8830203
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (50 mg), given 4 times daily for 3 days starting 2 hours after surgery (Trial 1)
Study: 8830203
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (50 mg), given 4 times daily for 3 days starting 3 hours after surgery (Trial 2)
Study: 8830203
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (50 mg)
Study: 6775298
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NGS) 0.75 mg
Study: 6775298
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (NGO) 15 mg
Study: 26823335
Drug: HRV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRV administered at 6 and 10 weeks (group 1)
Study: 26823335
Drug: HRV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRV administered at 10 and 14 weeks (group 2)
Study: 26823335
Drug: HRV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRV administered at 6, 10, and 14 weeks (group 3)
Study: 22781186
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg capsules of ginger root powder, three times a day)
Study: 22781186
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg capsules, three times a day)
Study: 19038375
Drug: 350‐mm(2) Baerveldt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350‐mm(2) Baerveldt glaucoma implant (tube group)
Study: 11926711
Drug: Non-invasive ventilation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive ventilation (NIV) plus standard medical therapy (ST)
Study: 11926711
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (ST) alone
Study: 8088297
Drug: anti-regurgitation formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-regurgitation formula with thickening product, positional treatment, parental reassurance
Study: 8088297
Drug: placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (same formula without thickening product, positional treatment, parental reassurance)
Study: 2764265
Drug: Pentaglobin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (10 g daily on the 3rd, 4th, and 5th day)
Study: 2764265
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin (12.5 g daily on the 3rd, 4th, and 5th day)
Study: 27606566
Drug: Enamelon® Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamelon® Preventive Treatment Gel (EPTG) with 0.4% stannous fluoride
Study: 27606566
Drug: Biotene® Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotene® Oral Balance Gel (BOBG)
Study: 25608984
Drug: Topical leek
Normalized name: Leek
DrugBank: Leek (DB10659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical leek extract cream
Study: 25608984
Drug: Standard antihemorrhoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihemorrhoid cream
Study: 22940055
Drug: 75 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 cGy 131-Iodine tositumomab with high-dose BEAM (carmustine, etoposide, cytarabine, and melphalan) followed by autologous stem cell transplantation
Study: 16818865
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment by experts
Study: 7531022
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus transcatheter hepatic artery infusion chemotherapy (TAI) and embolisation (IAE) treatment (Group B)
Study: 7531022
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus systemic chemotherapy (Group C)
Study: 3278764
Drug: O-(beta-hydroxyethyl)-rutosides (oxerutin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-(beta-hydroxyethyl)-rutosides (oxerutin; 'Paroven', 'Venoruton', Zyma) 3 g/day
Study: 30975645
Drug: Steroid (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid (methylprednisolone 40 mg)
Study: 28480412
Drug: liver‐softening medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: liver‐softening medicine plus glucosamine
Study: 23993865
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of maintenance medication
Study: 23993865
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of medication
Study: 29117091
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both expert and novice demonstrations
Study: 16783669
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (Group K: n=22)
Study: 16783669
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Group S: n=23)
Study: 7696447
Drug: Budesonide enema,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema, 2 mg/100 mL (Entocort)
Study: 7696447
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate foam enema, 125 mg (Colifoam)
Study: 2431838
Drug: Theophylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (600 mg daily)
Study: 2431838
Drug: Enprofylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (600 mg daily)
Study: 28732741
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert saline solution)
Study: 26710954
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml oral lactulose solution, twice a day for 4 weeks
Study: 2872809
Drug: Terazosin (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (once daily)
Study: 2872809
Drug: Prazosin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (twice daily)
Study: 28176470
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg (fasted) under unmodified gastric pH
Study: 28176470
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg (fasted) 1 hour after ranitidine 450 mg (elevated gastric pH)
Study: 24479279
Drug: G‐aenial Flo
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐aenial Flo bulk fill (GF)
Study: 24479279
Drug: G‐aenial Universal
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐aenial Universal Flo bulk fill (GUF)
Study: 20825806
Drug: Placebo lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lubricant gel
Study: 16388507
Drug: Group-1 (PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-1 (PSA cut-off of 4.0 ng/ml and/or abnormal DRE/TRUS)
Study: 16388507
Drug: Group-2 (PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-2 (PSA cut-off of 3.0 ng/ml)
Study: 11368132
Drug: Adding myeloperoxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding myeloperoxidase (280 ng/ml) to neutrophil granulocyte suspensions
Study: 9412638
Drug: Human pial
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human pial arteries contracted to KCl 30 mmol/L, norepinephrine 1 μmol/L, and vasopressin 0.1 μmol/L
Study: 9412638
Drug: Human pial
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human pial arteries relaxed to acetylcholine 3 μmol/L
Study: 8501160
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MMI daily
Study: 8501160
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg MMI daily
Study: 2820202
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement (5 g/day in Study I, 7 g/day in Study II)
Study: 31005551
Drug: Polypharmacy (≥6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (≥6 drugs)
Study: 28129275
Drug: Flexible Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible Daily Undulating Periodization (FDUP)
Study: 28129275
Drug: Traditional Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Daily Undulating Periodization (DUP)
Study: 25832541
Drug: Fresh red
Normalized name: Refresh Redness Relief
DrugBank: Polyvinyl alcohol (DB11060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fresh red onion meal (100 g providing 156.3 ± 3.4 μmol (47 mg) quercetin)
Study: 25832541
Drug: Quercetin dihydrate
Normalized name: Quercetin dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin dihydrate tablet (1800 ± 150 μmol (544 mg) of quercetin)
Study: 7972346
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (Valdispert forte, 405 mg t.i.d.)
Study: 1095248
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus ethambutol daily for 2 months and then once a week (ER7ER1)
Study: 1095248
Drug: Ethionamide plus
Normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethionamide plus pyrazinamide plus cycloserine daily for 6 months and then ethionamide plus pyrazinamide daily (EtZC)
Study: 1095248
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus ethambutol twice a week (ER2)
Study: 1095248
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus ethambutol daily (ER7)
Study: 29045169
Drug: Topical palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical palmitoylethanolamide (PEA) (Defluxa)
Study: 25483019
Drug: Greater daily
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater daily walking activity
Study: 25483019
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily walking activity
Study: 10612768
Drug: Diabetes mellitus
Normalized name: diagnostic,monitoring agents for diabetes mellitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes mellitus with a preoperative blood glucose level of 200 mg/dL or more
Study: 9578541
Drug: Standard antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiepileptic drugs (optimal doses)
Study: 8111800
Drug: Glyburide (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (1.25 or 2.5 mg/day)
Study: 8111800
Drug: Glipizide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (2.5 or 5 mg/day)
Study: 8111800
Drug: Glyburide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (mean dose 8.5 mg/day)
Study: 8111800
Drug: Glipizide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (mean dose 15.4 mg/day)
Study: 3903062
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cisplatin, doxorubicin, cyclophosphamide: PACe)
Study: 3903062
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (PACe)
Study: 29343527
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for NF1-OPG
Study: 29343527
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for sporadic OPG
Study: 9665503
Drug: Indinavir 400
Normalized name: indinavir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 400 mg with delavirdine
Study: 9665503
Drug: Indinavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 600 mg with delavirdine
Study: 9665503
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg alone
Study: 7544368
Drug: FK 506
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 506 treatment
Study: 912951
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune globulin (HBIG) administered at five to eight week intervals.
Study: 19467804
Drug: 3D‐CRT planning
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐CRT planning without mention of prostate or rectal contouring.
Study: 19022811
Drug: High-dose immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppressive therapy and autologous stem cell transplantation
Study: 16855072
Drug: Sitagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 200 mg bid
Study: 12500203
Drug: VPA-985 25
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA-985 25 mg twice daily
Study: 12500203
Drug: VPA-985 125
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA-985 125 mg twice daily
Study: 12500203
Drug: VPA-985 250
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA-985 250 mg twice daily
Study: 1297231
Drug: Glutathione (GSH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (GSH, 1200 mg, i.v.)
Study: 29025005
Drug: Extended-release paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release paracetamol (ER-APAP) 2 x 665 mg
Study: 27048210
Drug: Vortioxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (20 or 40 mg) with or without ethanol
Study: 25293834
Drug: Haptotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haptotherapy treatment
Study: 22516039
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing regimen (15 mg MTX once a week)
Study: 22516039
Drug: Accelerated dosing
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated dosing regimen (25 mg MTX once a week)
Study: 19853680
Drug: RUTI (5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTI (5-200 microg doses)
Study: 16116012
Drug: Ketamine sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine sedation (0.5 mg . kg(‐1) . h(‐1) continuous infusion after IV administration of 0.01 mg/kg midazolam)
Study: 16116012
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (volume-equivalent)
Study: 10408158
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) therapy for 2 weeks before LH-RH analogue injection
Study: 10408158
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) therapy for 4 weeks before LH-RH analogue injection
Study: 10408158
Drug: LH-RH analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH analogue injection
Study: 10408158
Drug: CMA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMA administration after LH-RH analogue application
Study: 7673760
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SPECT score >= 4 and/or ST-depression in >= 3 leads
Study: 28157491
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg dexamethasone (control)
Study: 28157491
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg and 8 mg dexamethasone
Study: 23332349
Drug: Docetaxel administered
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel administered concomitantly with capecitabine (DC)
Study: 19471901
Drug: Conventional detoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional detoxification treatment (KE)
Study: 15005830
Drug: Prandial subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial subcutaneous injections of rGLP-1 (76 nmol 30 min before meals, four times daily)
Study: 15005830
Drug: Prandial subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial subcutaneous injections of rGLP-1
Study: 15005830
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of rGLP-1 (12.7 nmol/h)
Study: 29684501
Drug: Sputum rheology
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum rheology measures (G', G" and solids content)
Study: 22832329
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol infusion (two concentrations)
Study: 22832329
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol infusion (highest dose level)
Study: 17934678
Drug: Routine asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine asthma outcome measures (beta2-agonist prescription rate and number of oral steroid courses)
Study: 15743537
Drug: Soy extract
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy extract capsules (2 capsules containing daidzin : genistin = 7.79 : 22.57 mg)
Study: 15743537
Drug: Soy beverage
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy beverage (prepared from 15 g of soy flour containing daidzin : genistin = 9.27 : 10.51 mg)
Study: 15743537
Drug: Soy extract
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy extract capsules
Study: 9052446
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet supplemented with 30 g per day of L-arginine for 3 days before surgery